Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,068.80down ₹28.70 (2.62%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,097.50.
30 Oct: open ₹1,050.00, high ₹1,076.90, low ₹972.00
52-week range of traded prices to 30 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,851 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 26,77,98551.0% delivered
Strides Pharma Science board meetings
114 filed, newest first. Page 3 of 3.
Oct 2009
20 Oct · Board meeting
Meeting on 30 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
20 Jul · Board meeting
Meeting on 30 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Apr 2009
15 Apr · Board meeting
Meeting on 24 Apr 2009: “Unaudited Financial Results for the qtr ended March 31, 2009”8 Apr · Board meeting
Inter-alia, consider various options of reorganizing the business of the Company and its Subsidiary Companies.
Feb 2009
16 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2008 and recommendation of dividend, if any.
Oct 2008
20 Oct · Board meeting
Meeting on 31 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
14 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended June 30, 2008.
Apr 2008
19 Apr · Board meeting
Meeting on 28 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Mar 2008
7 Mar · Board meeting
Board of Directors, at its meeting held on March 07, 2008 has not recommended any dividend for the year ended December 31, 2007.
Feb 2008
28 Feb · Board meeting
To consider inter-alia, the audited financial results of the company for the financial year ended December 31, 2007 and recommendation of dividend if any.
Oct 2007
16 Oct · Board meeting
Meeting on 30 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Jul 2007
19 Jul · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter/half year ended June 30, 2007.
Apr 2007
16 Apr · Board meeting
To consider inter-alia, the unaudited financial results of the Company for the quarter ended March 31,2007.
Jan 2007
19 Jan · Board meeting
To consider inter-alia, the audited financial results of the company (both stand alone & consolidated) for the financial year ended December 31,2006 and recommendation of dividend, if any.